Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate

Summary

Prothrombin complex concentrates (PCC) can rapidly normalise prolonged prothrombin time, induced by vitamin K antagonists (VKA). We conducted a multicentre retrospective study to investigate whether reversal of VKA coagulopathy with 4-factor PCC improves the survival of patients with VKA-related intracerebral haemorrhage as compared to plasma. We included 135 consecutive patients with VKA-related intracerebral haemorrhage treated either with plasma (mainly in Canada) or 4-factor PCC (The Netherlands and Sweden) for the reversal of VKA. Data on characteristics of the patients and the haemorrhage were collected. The volume of intracerebral haematoma was calculated from the first computed tomography (CT) scan. The unadjusted and adjusted odds ratio (OR) for 30-day all-cause mortality in both treatment groups was compared using logistic regression. Patients who received plasma (n=35, median 4 units) more often had diabetes, antiplatelet therapy, and intraventricular haemorrhage on the initial CT scans than patients who received PCC (n=100, median 22.5 IU/kg [interquartile range 20–26 IU], median of total dose 1,700 IU). The volume of intracerebral haematoma was larger in the plasma-treated group compared to the PCC-treated group (haematoma, mean 64.5 vs 36.0 cm³; p=0.021). The unadjusted OR for all-cause 30-day mortality in the PCC group was 0.40 (95% confidence interval, 0.18–0.87; p=0.021) compared to the plasma group. After adjusting for the haematoma volume, bleeding localisation and age, the effect of PCC on mortality became non-significant. In conclusion, treatment with 4-factor PCC for VKA reversal in patients with intracerebral haemorrhage does not seem to reduce the 30-day all-cause mortality compared to plasma.

Keywords

Vitamin K antagonists - intracerebral hemorrhage - prothrombin complex concentrates - plasma

• References

• 1 Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial haemorrhage. Facts and hypotheses. Stroke 1995; 26: 1471-1477.
• 2 Majeed A, Kim YK, Roberts RS. et al. Optimal timing of resumption of warfarin after intracranial haemorrhage. Stroke 2010; 41: 2860-2866.
• 3 Broderick JP, Brott TG, Duldner JE. et al. Volume of intracerebral haemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993; 24: 987-993.
• 4 Franke CL, van Swieten JC, Algra A. et al. Prognostic factors in patients with in-tracerebral haematoma. J Neurol Neurosurg Psychiatry 1992; 55: 653-657.
• 5 Fogelholm R, Murros K, Rissanen A. et al. Long term survival after primary in-tracerebral haemorrhage: a retrospective population based study. J Neurol Neur-osurg Psychiatry 2005; 76: 1534-1538.
• 6 Tuhrim S, Dambrosia JM, Price TR. et al. Intracerebral haemorrhage: external validation and extension of a model for prediction of 30-day survival. Ann Neurol 1991; 29: 658-663.
• 7 Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007; 21: 37-48.
• 8 Makris M, Greaves M, Phillips WS. et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-480.
• 9 Lee SB, Manno EM, Layton KF. et al. Progression of warfarin-associated intracerebral haemorrhage after INR normalisation with FFP. Neurology 2006; 67: 1272-1274.
• 10 Barrett NA, Kam PC. Transfusion-related acute lung injury: a literature review. Anaesthesia 2006; 61: 777-785.
• 11 Majeed A, Eelde A, Agren A. et al. Thromboembolic safety and efficacy of pro-thrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res 2012; 129: 146-151.
• 12 Samama CM. Prothrombin complex concentrates: a brief review. Eur J Anaes- thesiol 2008; 25: 784-789.
• 13 Dowlatshahi D, Butcher KS, Asdaghi N. et al. Poor prognosis in warfarin-associated intracranial haemorrhage despite anticoagulation reversal. Stroke 2012; 43: 1812-1817.
• 14 Hanger HC, Geddes JA, Wilkinson TJ. et al. Warfarin-related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates. Intern Med J 2013; 43: 308-316.
• 15 Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349: 675-683.
• 16 Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
• 17 Hansen ML, Sorensen R, Clausen MT. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441.